Sigmanomics
Back to all insights

Breaking News: Lexaria Biosciences Begins Patient Dosing in Phase B Study, According to HC Wainwright

Breaking News: Lexaria Biosciences Begins Patient Dosing in Phase B Study, According to HC Wainwright

Exciting Developments in Bioscience

H.C. Wainwright has recently reiterated a Buy rating and $10 price target on Lexaria Bioscience shares. This comes after the company’s announcement that the Phase 1b 12-week chronic study in Australia has officially commenced patient dosing as planned. The GLP-1-H24-4 study is a significant step forward for Lexaria Biosciences, as it includes four planned DehydraTECH formulation arms and one Rybelsus comparator control arm.

The Study Details

The GLP-1-H24-4 study is set to enroll a total of 20 overweight, obese, pre-, or type 2 diabetic patients for each of arms 1-4 at seven clinical sites. Additionally, the DehydraTECH-tirzepatide Arm 5 will be added at a later date if supported by positive results from the separate ongoing study GLP-1-H24-3. This exciting development opens up new possibilities within the GLP-1 sector, potentially expanding the application of the DehydraTECH delivery technology.

How will this affect you?

For individuals who are struggling with weight management or diabetes, the outcome of this study could potentially lead to new and innovative treatment options. If successful, the DehydraTECH delivery technology could revolutionize how medication is administered and absorbed in the body. This could ultimately lead to more effective and efficient treatment strategies for those in need.

How will this affect the world?

The implications of this study extend far beyond individual patients. The advancement of technology in the bioscience sector has the potential to impact the healthcare industry as a whole. With the possibility of expanding the application of DehydraTECH delivery technology, we could see significant improvements in drug delivery methods and treatment outcomes for a wide range of medical conditions. This could pave the way for more cutting-edge research and development in the field of bioscience.

Conclusion

As Lexaria Biosciences embarks on this groundbreaking Phase B study, the future of bioscience looks bright. With the support and enthusiasm of H.C. Wainwright, the potential for innovation and advancement in drug delivery technology is truly exciting. We eagerly await the results of the GLP-1-H24-4 study and the impact it will have on both individuals and the world at large.

more insights

“Breaking News: President Trump Opens Doors for Banks to Safely Store Bitcoin and Other Crypto Assets with the Elimination of SAB 121”

January 24, 2025

President Trump has officially eliminated a controversial guideline from the U.S. Securities and Exchange Commission that effectively prevented US banks from holding crypto assets. The new administration just rescinded Staff Accounting Bulletin 121, which forced banks to identify crypto assets held on behalf of their customers as liabilities on their

Read more >
Sigmanomics

Menu

About

News

Signals

Risk Disclaimer: Sigmanomics is a financial portal that provides news and analysis about the different financial markets. The articles that we serve on the portal depend solely on the opinion and analysis of our economists which in no way are intended to incite a visitor of the website or an investor to trade or sell/buy a certain instrument. It is the responsibility of the visitor / trader only to evaluate his trading strategies and whether he is capable of trading with taking into consideration that losing all the capital invested is a possibility. The visitor should seek an independent professional financial advisor to discuss his or her trading strategies. Moreover, the provided rates for the different instruments are indicative only and cannot be used for trading purposes. Therefore, no responsibility can be imposed on sigmanomics.com.com and the company operating the portal for any loss of money that may occur to the visitor by using the website.